Liafensine

利阿芬辛

Report date: 2025/03/03 10:50:39
NMEFirst In Class

Base Information

Drug NameLiafensine
Drug Alias Name立阿芬辛liafensinaliafensinumDB-104BMS-820836
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsDopamine reuptake inhibitors
TargetsNorepinephrine transporterDopamine transporterSerotonin transporter
Therapy Area/IndicationsDepressive Disorder, Treatment-ResistantDepression
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAmriBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesChuang Yi Global Asset Management Co LtdDenovo Biopharma LlcPatheon Inc
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsDepressive Disorder, Treatment-Resistant
Inactive IndicationsDepression

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG